The FDA placed a clinical hold on the Phase 2 study of Rocket Pharmaceuticals Inc. on August 11, 2025.
2 reports, 2 independent
Updated Aug 4
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA placed a clinical hold on the Phase 2 study of Rocket Pharmaceuticals Inc. on August 11, 2025.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA approved the relaunch of Rocket's clinical trial following a previous clinical hold.1 source
FDA placed clinical hold on Rocket Pharma's Phase 2 study.1 source
Keep exploring
The entities involved
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
- FDA approval enables commercial availability for a product associated with Indianapolis.
- Yamo Pharmaceuticals LLC plans to conduct a Phase 3 study in the US, with drug development regulated by the FDA.
- Arthur Caplan questioned the FDA regarding the status of clinical trials in 2006.
Coverage
Newest first; wire copies grouped- yahoo.com
- prnewswire_rocketClass Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT) - August 11, 2025 Deadline to Join - Contact The Gross Law Firm